B. Riley Predicts Vaxart’s Q1 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT) – Research analysts at B. Riley raised their Q1 2025 earnings per share (EPS) estimates for shares of Vaxart in a note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now expects that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.09). B. Riley has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart’s Q2 2025 earnings at ($0.08) EPS and Q3 2025 earnings at ($0.07) EPS.

Vaxart Trading Down 2.7 %

NASDAQ:VXRT opened at $0.41 on Monday. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.69. Vaxart has a 1-year low of $0.39 and a 1-year high of $1.34. The stock has a market capitalization of $93.46 million, a PE ratio of -1.00 and a beta of 1.69.

Vaxart (NASDAQ:VXRT) last announced its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.

Institutional Trading of Vaxart

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Graham Capital Management L.P. lifted its stake in Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 32,482 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after buying an additional 35,213 shares in the last quarter. Invesco Ltd. lifted its position in shares of Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock worth $50,000 after buying an additional 24,803 shares during the last quarter. XTX Topco Ltd boosted its stake in Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 122,387 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 17,942 shares during the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.